BCAL Diagnostics: Half Yearly Report and Accounts
Filed with ASX · · 23 pages · English
BCAL Diagnostics Limited on 6ix
Earlier from BCAL Diagnostics
- Shareholder Update
- Quarterly Activities/Appendix 4C Cash Flow Report
- BCAL Early Cancer Detection Tests Update
- BCAL Establishes $10m Convertible Note Facility Revised
- BCAL Establishes $10 million Convertible Note Facility
Later from BCAL Diagnostics
- BCAL Accelerates Rollout of Avantect Early Detection Tests
- BCAL Appoints Anne-Louise Arnett as Chief Executive Officer
- BCAL Launches Early Detection Cancer Platform
- BCAL Develops New Blood Test for Breast Cancer Recurrence
- BCAL Secures Funding for FY2027
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics